Compare ZYME & CCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZYME | CCS |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2017 | 2014 |
| Metric | ZYME | CCS |
|---|---|---|
| Price | $22.83 | $65.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $32.75 | ★ $74.80 |
| AVG Volume (30 Days) | ★ 900.1K | 260.7K |
| Earning Date | 03-04-2026 | 01-28-2026 |
| Dividend Yield | N/A | ★ 1.79% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 6.93 |
| Revenue | $134,481,000.00 | ★ $4,157,669,000.00 |
| Revenue This Year | $64.19 | N/A |
| Revenue Next Year | $91.98 | $8.74 |
| P/E Ratio | ★ N/A | $9.37 |
| Revenue Growth | ★ 116.21 | N/A |
| 52 Week Low | $9.03 | $50.42 |
| 52 Week High | $28.49 | $81.10 |
| Indicator | ZYME | CCS |
|---|---|---|
| Relative Strength Index (RSI) | 39.82 | 51.84 |
| Support Level | $22.80 | $65.40 |
| Resistance Level | $24.31 | $70.60 |
| Average True Range (ATR) | 1.16 | 2.99 |
| MACD | -0.19 | 0.05 |
| Stochastic Oscillator | 18.51 | 59.13 |
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Century Communities Inc is engaged in the development, design, construction, marketing, and selling of single-family attached and detached homes. It has five homebuilding segments: West, Mountain, Texas, Southeast, and Century Complete. Its sixth reportable segment is financial services operations, which provides mortgage, title, and insurance services to homebuyers. It has acquired land for homebuilding operations with the primary intent to develop and construct single-family detached or attached homes for sale on the acquired land. The company sells homes through its sales representatives and independent real estate brokers. The company generates the majority of its revenue from the Mountain segment.